P
SBBP

&Partners’s Strongbridge Biopharma plc. SBBP Stock Holding History

&Partners’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-15,000
Closed -$28K – 168
2020
Q1 		$28K Hold
15,000
– – 0.04% 141
2019
Q4 		$31K Buy
+15,000
New +$28.8K 0.04% 161

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

&Partners's SBBP Position: Q2 2020 in Review

&Partners sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2020, closing a stake of 15,000 shares — an estimated $28K sold.

&Partners first reported a position in SBBP in Q4 2019 and held it in 2 quarters. The position peaked at $31K in Q4 2019. 69 funds tracked by Wall St. Rank hold SBBP as of Q2 2020.

  • &Partners reported no remaining Strongbridge Biopharma plc. position as of Q2 2020 after selling out during the quarter.
  • &Partners sold 15,000 Strongbridge Biopharma plc. shares in Q2 2020, an estimated $28K.
  • &Partners first reported a position in Strongbridge Biopharma plc. in Q4 2019 and held it in 2 quarters.
  • &Partners's Strongbridge Biopharma plc. position peaked at $31K in Q4 2019.
  • 69 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2020.

Based on &Partners's 13F filing for Q2 2020, filed 7 Jul 2020.